How Oligonucleotides Target C9orf72 for Brain Diseases

This patent describes using special genetic molecules called oligonucleotides to treat brain diseases like ALS and FTD by targeting a specific gene called C9orf72.

What it covers

The patent describes specific oligonucleotide compositions designed to interact with the C9orf72 gene. These oligonucleotides are intended to be used in methods for treating conditions linked to this gene, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). For example, a patient with C9orf72-associated ALS could receive a composition containing these oligonucleotides to potentially reduce the harmful effects of the gene.

What it doesn't cover

• —Does not cover treatments for ALS or FTD that are not linked to the C9orf72 gene mutation.
• —Does not cover therapies for C9orf72-associated conditions that use non-oligonucleotide approaches, such as small molecule drugs or gene editing tools like CRISPR.
• —Does not cover diagnostic methods for identifying the C9orf72 mutation.
• —Does not cover oligonucleotides designed to target genes other than C9orf72.

The clever bit

The clever bit is precisely designing oligonucleotide molecules to specifically interfere with the C9orf72 gene, which is known to cause certain forms of ALS and FTD. This targeted approach aims to correct or mitigate the genetic defect rather than just treating symptoms.

Why it matters

This patent addresses severe neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), which currently have limited treatment options. The C9orf72 gene mutation is a major genetic cause for both conditions, making targeted therapies crucial. Developing specific oligonucleotides to modulate this gene could offer a new therapeutic approach for patients suffering from these debilitating diseases.

Real-world examples

• 1.Investigational oligonucleotide therapies for C9orf72-ALS
• 2.Antisense oligonucleotide drugs in development
• 3.Gene-targeted treatments for neurodegenerative disorders